Sfoglia per Rivista CANCER CHEMOTHERAPY AND PHARMACOLOGY
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
2012-01-01 Reni, M; Cereda, S; Rognone, A; Belli, C; Ghidini, M; Longoni, S; Fugazza, C; Rezzonico, S; Passoni, P; Slim, N; Balzano, G; Nicoletti, R; Cappio, S; Doglioni, Claudio; Villa, E.
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma
2016-01-01 Cereda, S; Milella, M; Cordio, S; Leone, F; Aprile, G; Galiano, A; Mosconi, S; Vasile, E; Santini, D; Belli, C; Auriemma, A; Novarino, A; Vaccaro, V; Martines, C; Marino, D; Lutrino, Se; Palazzo, V; Reinach, B; Aldrighetti, L; Reni, M
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes
2023-01-01 Militello, A. M.; Orsi, G.; Cavaliere, A.; Niger, M.; Avallone, A.; Salvatore, L.; Tortora, G.; Rapposelli, I. G.; Giordano, G.; Noventa, S.; Giommoni, E.; Bozzarelli, S.; Macchini, M.; Peretti, U.; Procaccio, L.; Puccini, A.; Cascinu, S.; Montagna, C.; Milella, M.; Reni, M.
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma
2007-01-01 Reni, M; Cereda, S; Bonetto, E; Vigano, Mg; Passoni, P; Zerbi, A; Balzano, G; Nicoletti, R; Staudacher, C; Di Carlo, V
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients
2020-01-01 Macchini, M.; Peretti, U.; Orsi, G.; Zanon, S.; Mazza, E.; Valente, M. M.; Tamburrino, D.; Belfiori, G.; Rossi, G.; Testoni, S. G. G.; Passoni, P.; Doglioni, C.; Cascinu, S.; Reni, M.
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study
2012-01-01 A., Zaniboni; E., Aitini; S., Barni; D., Ferrari; Cascinu, Stefano; V., Catalano; G., Valmadre; D., Ferrara; E., Veltri; C., Codignola; R., Labianca
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
2009-01-01 Brandes, Aa; Tosoni, A; Franceschi, E; Blatt, V; Santoro, A; Faedi, M; Amista, P; Gardiman, M; Labianca, R; Bianchini, C; Ermani, M; Reni, M
Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: A randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
2016-01-01 Mazza, E; Brandes, A; Zanon, S; Eoli, M; Lombardi, G; Faedi, M; Franceschi, E; Reni, M
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma
2009-01-01 Reni, ; Cereda, ; Balzano, ; Passoni, ; Rognone, ; Zerbi, ; Nicoletti, ; Mazza, ; Arcidiacono, P. G.; Di, Carlo; Villa, ; Reni, Michele
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial
2010-01-01 Cascinu, S; Galizia, E; Labianca, R; Ferraù, F; Pucci, F; Silva, Rr; Luppi, G; Beretta, Gd; Berardi, R; Scartozzi, M
Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors
2017-01-01 Aspeslagh, S; Shailubhai, K; Bahleda, R; Gazzah, A; Varga, A; Hollebecque, A; Massard, C; Spreafico, A; Reni, M; Soria, J-C
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
2010-01-01 Loupakis, F.; Masi, G.; Fornaro, L.; Vasile, E.; Allegrini, G.; Fontana, E.; Granetto, C.; Salvatore, L.; Mentuccia, L.; Andreuccetti, M.; Cortesi, E.; Merlano, M.; Cascinu, S.; Falcone, A.
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma
2016-01-01 Belli, Carmen; Piemonti, Lorenzo; D'Incalci, Maurizio; Zucchetti, Massimo; Porcu, Luca; Cappio, Stefano; Doglioni, Claudio; Allavena, Paola; Ceraulo, Domenica; Maggiora, Paola; Dugnani, Erica; Cangi Maria, Giulia; Garassini, Greta; Reni, Michele
Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma
2020-01-01 Reni, M.; Peretti, U.; Zanon, S.; Macchini, M.; Balzano, G.; Mazza, E.; Tamburrino, D.; Orsi, G.; Arcidiacono, P. G.; Falconi, M.; Gianni, L.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). | 1-gen-2012 | Reni, M; Cereda, S; Rognone, A; Belli, C; Ghidini, M; Longoni, S; Fugazza, C; Rezzonico, S; Passoni, P; Slim, N; Balzano, G; Nicoletti, R; Cappio, S; Doglioni, Claudio; Villa, E. | |
| Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma | 1-gen-2016 | Cereda, S; Milella, M; Cordio, S; Leone, F; Aprile, G; Galiano, A; Mosconi, S; Vasile, E; Santini, D; Belli, C; Auriemma, A; Novarino, A; Vaccaro, V; Martines, C; Marino, D; Lutrino, Se; Palazzo, V; Reinach, B; Aldrighetti, L; Reni, M | |
| Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes | 1-gen-2023 | Militello, A. M.; Orsi, G.; Cavaliere, A.; Niger, M.; Avallone, A.; Salvatore, L.; Tortora, G.; Rapposelli, I. G.; Giordano, G.; Noventa, S.; Giommoni, E.; Bozzarelli, S.; Macchini, M.; Peretti, U.; Procaccio, L.; Puccini, A.; Cascinu, S.; Montagna, C.; Milella, M.; Reni, M. | |
| Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma | 1-gen-2007 | Reni, M; Cereda, S; Bonetto, E; Vigano, Mg; Passoni, P; Zerbi, A; Balzano, G; Nicoletti, R; Staudacher, C; Di Carlo, V | |
| Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients | 1-gen-2020 | Macchini, M.; Peretti, U.; Orsi, G.; Zanon, S.; Mazza, E.; Valente, M. M.; Tamburrino, D.; Belfiori, G.; Rossi, G.; Testoni, S. G. G.; Passoni, P.; Doglioni, C.; Cascinu, S.; Reni, M. | |
| FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study | 1-gen-2012 | A., Zaniboni; E., Aitini; S., Barni; D., Ferrari; Cascinu, Stefano; V., Catalano; G., Valmadre; D., Ferrara; E., Veltri; C., Codignola; R., Labianca | |
| Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) | 1-gen-2009 | Brandes, Aa; Tosoni, A; Franceschi, E; Blatt, V; Santoro, A; Faedi, M; Amista, P; Gardiman, M; Labianca, R; Bianchini, C; Ermani, M; Reni, M | |
| Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: A randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) | 1-gen-2016 | Mazza, E; Brandes, A; Zanon, S; Eoli, M; Lombardi, G; Faedi, M; Franceschi, E; Reni, M | |
| Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma | 1-gen-2009 | Reni, ; Cereda, ; Balzano, ; Passoni, ; Rognone, ; Zerbi, ; Nicoletti, ; Mazza, ; Arcidiacono, P. G.; Di, Carlo; Villa, ; Reni, Michele | |
| Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial | 1-gen-2010 | Cascinu, S; Galizia, E; Labianca, R; Ferraù, F; Pucci, F; Silva, Rr; Luppi, G; Beretta, Gd; Berardi, R; Scartozzi, M | |
| Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors | 1-gen-2017 | Aspeslagh, S; Shailubhai, K; Bahleda, R; Gazzah, A; Varga, A; Hollebecque, A; Massard, C; Spreafico, A; Reni, M; Soria, J-C | |
| Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma | 1-gen-2010 | Loupakis, F.; Masi, G.; Fornaro, L.; Vasile, E.; Allegrini, G.; Fontana, E.; Granetto, C.; Salvatore, L.; Mentuccia, L.; Andreuccetti, M.; Cortesi, E.; Merlano, M.; Cascinu, S.; Falcone, A. | |
| Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma | 1-gen-2016 | Belli, Carmen; Piemonti, Lorenzo; D'Incalci, Maurizio; Zucchetti, Massimo; Porcu, Luca; Cappio, Stefano; Doglioni, Claudio; Allavena, Paola; Ceraulo, Domenica; Maggiora, Paola; Dugnani, Erica; Cangi Maria, Giulia; Garassini, Greta; Reni, Michele | |
| Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma | 1-gen-2020 | Reni, M.; Peretti, U.; Zanon, S.; Macchini, M.; Balzano, G.; Mazza, E.; Tamburrino, D.; Orsi, G.; Arcidiacono, P. G.; Falconi, M.; Gianni, L. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile